0.86
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CytoMed Therapeutics
Its shares trade under the ticker GDTC. It has been listed since 14 April 2023. In the fiscal year to 31 December 2025, it reported revenue of SGD 319,201 and a net loss of SGD 3.9m. At that date it held total assets of SGD 8.0m and shareholders' equity of SGD 6.5m.
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 28 full-time employees The company went IPO on 2023-04-14. The firm is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. The company is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Apr 2023
- Employees
- 28
- Website
- cytomed.sg ↗
- Head office
- #08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, U0, 149544
- Incorporated in
- U0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Loh HanDirector
- Yew HuaDirector
- Zeng JiemingDirector
- Mark Leong Kei WeiDirector
- Toh KiatDirector
- Tan Wee KiatDirector
- Choo KongDirector
- Dr. Tien Wee LukDirector
- Wu ThomasDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CytoMed Therapeutics Ltd. has 28 full-time employees focused on biopharmaceutical development.
- CTM-N2D is the lead product candidate using NKG2DL-targeting CAR technology.
- The company leverages licensed proprietary technologies for cell-based immunotherapies.
Weaknesses
- The company has only 28 employees, which may limit development capacity.
- CTM-N2D is the lead product candidate with no other candidates in late-stage development.
- The company's IPO was on 14 April 2023, indicating recent market entry.
Opportunities
- The company's focus on solid tumor treatments addresses a significant unmet medical need.
- The development of CTM-GDT for expanded allogeneic gamma delta T cells offers potential market expansion.
- iPSC-gdNKT technology could provide a new approach to cancer therapy.
Threats
- The biotechnology sector faces intense competition for cell-based immunotherapies.
- The company's reliance on three product candidates creates dependency on their success.
- Regulatory challenges may delay the approval of cell-based therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.